Anzeige
Erschienen in:
16.06.2020 | Original Article
Trends in long-term glucocorticoid use and risk of 5-year mortality: a historical cohort study in South Korea
Erschienen in: Endocrine | Ausgabe 3/2020
Einloggen, um Zugang zu erhaltenAbstract
Purpose
This study investigated trends in chronic glucocorticoid (GC) use in South Korea, and determined the association between chronic GC use and 5-year all-cause mortality.
Methods
A sample cohort was extracted from the South Korean National Health Insurance database. Patients prescribed a continuous dose of GC for ≥30 days were defined as chronic GC users. Time-dependent Cox regression was used for statistical analysis, and chronic GC exposure was considered a time-varying variable.
Results
The prevalence of chronic GC use gradually increased from 0.16% in 2002 to 0.54% in 2015. In the 2010 cohort (n = 822,097), chronic GC users had a significantly 1.41-fold higher 5-year all-cause mortality compared with controls [hazard ratio: 1.41, 95% confidence interval (CI): 1.28–1.55, P < 0.001]. On sensitivity analysis, chronic high-dose GC users showed 1.52-fold (HR: 1.52, 95% CI: 1.32–1.76; P < 0.001) and low-dose GC users showed 1.34-fold (HR: 1.34, 95% CI: 1.18–1.51; P < 0·001) higher 5-year all-cause mortality, compared with controls; the disease-specific 5-year mortality risk in chronic GC users was highest due to musculoskeletal disease (HR: 9.50), followed by infectious and parasitic diseases (HR: 2.43), and respiratory disease (HR: 2.18).
Conclusions
Numbers of chronic GC users gradually increased during 2002–2015; chronic GC use increased risks of 5-year all-cause mortality in the general adult South Korean population. This association was more evident among high-dose GC users (>5 mg/day of prednisolone). The risk of disease-specific mortality among chronic GC users was increased in those with musculoskeletal, infectious and parasitic, and respiratory diseases.